Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Alan K. Davis, Sara So, Rafael Lancelotta, Joseph P. Barsuglia & Roland R. Griffiths. (2019) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse 45:2, pages 161-169.
Read now
Read now
Albert Garcia-Romeu & William A. Richards. (2018) Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30:4, pages 291-316.
Read now
Read now
Hong-Wu Shen, Xi-Ling Jiang & Ai-Ming Yu. (2009) Development of a LC–MS/MS Method to Analyze 5-Methoxy-N,N-Dimethyltryptamine and Bufotenine: Application to Pharmacokinetic Study. Bioanalysis 1:1, pages 87-95.
Read now
Read now
D. Eric Brush, Steven B. Bird & Edward W. Boyer. (2004) Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances. Journal of Toxicology: Clinical Toxicology 42:2, pages 191-195.
Read now
Read now
Articles from other publishers (54)
Annie C. Souza, Bryan C. Souza, Arthur França, Marzieh Moradi, Nicholy C. Souza, Katarina E. Leão, Adriano B. L. Tort, Richardson N. Leão, Vítor Lopes-dos-Santos & Sidarta Ribeiro. (2024) 5-MeO-DMT induces sleep-like LFP spectral signatures in the hippocampus and prefrontal cortex of awake rats. Scientific Reports 14:1.
Crossref
Crossref
Stephan C. Tap. (2024)
The potential of 5‐methoxy‐
N,N
‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
. Addiction Biology 29:4.
Crossref
Crossref
Gustavo Almeida e Silva, Vinícius Galvão Wakui, Lucília Kato & Cássia A. Marquezin. (2024) Spectroscopic behavior of bufotenine and bufotenine N-oxide: Solvent and pH effects and interaction with biomembrane models. Biochimica et Biophysica Acta (BBA) - Biomembranes 1866:4, pages 184304.
Crossref
Crossref
Kenneth Shinozuka, Burton J. TabaacAlejandro ArenasBryce D. BeutlerKirsten CherianViviana D. EvansChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca. American Journal of Therapeutics 31:2, pages e112-e120.
Crossref
Crossref
Michellen Santos de Carvalho, Guilherme Vieira Botelho de Almeida, Karuppusamy Arunachalam, Edson Moleta Colodel, Camilo Eduardo Barcenas Olaya & Domingos Tabajara de Oliveira Martins. (2024) Evaluation of the toxicity of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb. in in vitro and in vivo models. Journal of Ethnopharmacology 319, pages 117171.
Crossref
Crossref
Anya Ragnhildstveit, Ryan Khan, Paul Seli, Lisa Claire Bass, River Jude August, Miriam Kaiyo, Nathaniel Barr, Laura Kate Jackson, Michael Santo Gaffrey, Joseph Peter Barsuglia & Lynnette Astrid Averill. (2023) 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study. Frontiers in Psychiatry 14.
Crossref
Crossref
Ana María Ortiz Bernal, Charles L. Raison, Rafael L. Lancelotta & Alan K. Davis. (2022) Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Frontiers in Psychiatry 13.
Crossref
Crossref
Claudius Lenz, Sebastian Dörner, Felix Trottmann, Christian Hertweck, Alexander Sherwood & Dirk Hoffmeister. (2022) Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines. ChemBioChem 23:13.
Crossref
Crossref
Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo, Alan K. Davis, Rafael Lancelotta, Natasha L. Mason & Johannes G. Ramaekers. (2022) The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT). Journal of Neurochemistry 162:1, pages 128-146.
Crossref
Crossref
Anna O Ermakova, Fiona Dunbar, James Rucker & Matthew W Johnson. (2021) A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology 36:3, pages 273-294.
Crossref
Crossref
Justin C. Strickland & Matthew W. Johnson. 2022. Behavioral Pharmacology of Drug Abuse: Current Status. Behavioral Pharmacology of Drug Abuse: Current Status
105
132
.
Shaun L. Greene. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
495
532
.
Máté Kapitány-Fövény, Ornella Corazza, Shanna Marrinan & Zsolt Demetrovics. 2020. The Cambridge Handbook of Substance and Behavioral Addictions. The Cambridge Handbook of Substance and Behavioral Addictions
307
325
.
. 2020. The Cambridge Handbook of Substance and Behavioral Addictions. The Cambridge Handbook of Substance and Behavioral Addictions
295
425
.
. 2020. The Cambridge Handbook of Substance and Behavioral Addictions. The Cambridge Handbook of Substance and Behavioral Addictions.
Nathan D. Sepeda, John M. Clifton, Laura Y. Doyle, Rafael Lancelotta, Roland R. Griffiths & Alan K. Davis. (2020) Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies 4:2, pages 114-122.
Crossref
Crossref
Dino Luethi & Matthias E. Liechti. (2020) Designer drugs: mechanism of action and adverse effects. Archives of Toxicology 94:4, pages 1085-1133.
Crossref
Crossref
Malin V Uthaug, Rafael Lancelotta, Attila Szabo, Alan K Davis, Jordi Riba & Johannes G Ramaekers. (2019) Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology 237:3, pages 773-785.
Crossref
Crossref
C. Hess & A. Boehmer. (2020) Toxicology of natural and synthetic aphrodisiacsToxikologie natürlicher und synthetischer Aphrodisiaka. Rechtsmedizin 30:1, pages 15-30.
Crossref
Crossref
Alan K. Davis, Lynnette A. Averill, Nathan D. Sepeda, Joseph P. Barsuglia & Timothy Amoroso. (2020) Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress 4, pages 247054702093956.
Crossref
Crossref
Joseph J. Palamar & Patricia Acosta. (2020) A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines. Human Psychopharmacology: Clinical and Experimental 35:1.
Crossref
Crossref
Christopher B. Germann. (2019) 5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity. Activitas Nervosa Superior 61:4, pages 170-216.
Crossref
Crossref
Helena Horta-Tricallotis, Javier Echeverría, Verónica Lema, Alethia Quirgas & Alejandra Vidal. (2019) Enema syringes in South Andean hallucinogenic paraphernalia: evidence of their use in funerary contexts of the Atacama and neighboring zones (ca. AD 500–1500). Archaeological and Anthropological Sciences 11:11, pages 6197-6219.
Crossref
Crossref
M. V. Uthaug, R. Lancelotta, K. van Oorsouw, K. P. C. Kuypers, N. Mason, J. Rak, A. Šuláková, R. Jurok, M. Maryška, M. Kuchař, T. Páleníček, J. Riba & J. G. Ramaekers. (2019) A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology 236:9, pages 2653-2666.
Crossref
Crossref
M. Rosaria Varì, Simona Pichini, Raffaele Giorgetti & Francesco P. Busardò. (2018) New psychoactive substances—Synthetic stimulants. WIREs Forensic Science 1:2.
Crossref
Crossref
Joseph Barsuglia, Alan K. Davis, Robert Palmer, Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Martin Polanco, Robert Grant & Roland R. Griffiths. (2018) Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. Frontiers in Psychology 9.
Crossref
Crossref
Alan K Davis, Joseph P Barsuglia, Rafael Lancelotta, Robert M Grant & Elise Renn. (2018)
The epidemiology of 5-methoxy-
N, N
-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
. Journal of Psychopharmacology 32:7, pages 779-792.
Crossref
Crossref
Joseph P. Barsuglia, Martin Polanco, Robert Palmer, Benjamin J. Malcolm, Benjamin Kelmendi & Tanya Calvey. 2018. Psychedelic Neuroscience. Psychedelic Neuroscience
121
158
.
Torsten Passie & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
69
110
.
Robson Savoldi, Daniel Polari, Jaquelinne Pinheiro-da-Silva, Priscila F. Silva, Bruno Lobao-Soares, Mauricio Yonamine, Fulvio A. M. Freire & Ana C. Luchiari. (2017) Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish. Frontiers in Behavioral Neuroscience 11.
Crossref
Crossref
Curtis P. Snook. 2017. Critical Care Toxicology. Critical Care Toxicology
1587
1607
.
Xi-Ling Jiang, Hong-Wu Shen, Donald E. Mager, Stephan Schmidt & Ai-Ming Yu. (2016) Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharmaceutica Sinica B 6:5, pages 492-503.
Crossref
Crossref
Xi-Ling Jiang, Hong-Wu Shen & Ai-Ming Yu. (2016) Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. Pharmacological Reports 68:3, pages 608-615.
Crossref
Crossref
Adam L. Halberstadt. (2016) Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacology Biochemistry and Behavior 143, pages 1-10.
Crossref
Crossref
Curtis P. Snook. 2016. Critical Care Toxicology. Critical Care Toxicology
1
22
.
Ana Margarida Araújo, Félix Carvalho, Maria de Lourdes Bastos, Paula Guedes de Pinho & Márcia Carvalho. (2015) The hallucinogenic world of tryptamines: an updated review. Archives of Toxicology 89:8, pages 1151-1173.
Crossref
Crossref
Xi-Ling Jiang, Hong-Wu Shen & Ai-Ming Yu. (2015) Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. Neuropharmacology 89, pages 342-351.
Crossref
Crossref
Ryan H.A. Chan & John E. Mendelson. 2014. The Effects of Drug Abuse on the Human Nervous System. The Effects of Drug Abuse on the Human Nervous System
533
552
.
Javier Echeverría & Hermann M. Niemeyer. (2013) Nicotine in the hair of mummies from San Pedro de Atacama (Northern Chile). Journal of Archaeological Science 40:10, pages 3561-3568.
Crossref
Crossref
Xi-Ling Jiang, Hong-Wu Shen, Donald E. Mager & Ai-Ming Yu. (2013)
Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-
N,N
-Dimethyltryptamine, and the Impact of CYP2D6 Status
. Drug Metabolism and Disposition 41:5, pages 975-986.
Crossref
Crossref
Shaun L. Greene. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances
363
381
.
Alexander V. LyubimovAndrew Bessire, Kuresh Youdim, Susan Hurst & Caroline A. Lee. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
88
.
Adam L. Halberstadt, David E. Nichols & Mark A. Geyer. (2012) Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology 221:4, pages 709-718.
Crossref
Crossref
Donald G. Barceloux. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse
768
780
.
Simon D. Brandt, Ruchanok Tearavarich, Nicola Dempster, Nicholas V. Cozzi & Paul F. Daley. (2012)
Synthesis and characterization of 5‐methoxy‐2‐methyl‐
N
,
N
‐dialkylated tryptamines
. Drug Testing and Analysis 4:1, pages 24-32.
Crossref
Crossref
J.C. Winter, D.J. Amorosi, Kenner C. Rice, Kejun Cheng & Ai-Ming Yu. (2011) Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice. Pharmacology Biochemistry and Behavior 99:3, pages 311-315.
Crossref
Crossref
Hong-Wu Shen, Xi-Ling Jiang & Ai-Ming Yu. (2011)
Nonlinear Pharmacokinetics of 5-Methoxy-
N,N
-dimethyltryptamine in Mice
. Drug Metabolism and Disposition 39:7, pages 1227-1234.
Crossref
Crossref
Hong-Wu Shen, Chao Wu, Xi-Ling Jiang & Ai-Ming Yu. (2010) Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. Biochemical Pharmacology 80:1, pages 122-128.
Crossref
Crossref
Simon D. Brandt, Sri Subha Tirunarayanapuram, Sally Freeman, Nicola Dempster, Steven A. Barker, Paul F. Daley, Nicholas V. Cozzi & Cláudia P. B. Martins. (2008)
Microwave‐accelerated synthesis of psychoactive deuterated
N
,
N
‐dialkylated‐[
α
,
α
,
β
,
β
‐d
4
]‐tryptamines
. Journal of Labelled Compounds and Radiopharmaceuticals 51:14, pages 423-429.
Crossref
Crossref
Ai-Ming Yu. (2008) Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions. The AAPS Journal 10:2.
Crossref
Crossref
Kenji Tsujikawa, Hiroyuki Mohri, Kenji Kuwayama, Hajime Miyaguchi, Yuko Iwata, Akinaga Gohda, Sunao Fukushima, Hiroyuki Inoue & Tohru Kishi. (2006) Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. Forensic Science International 164:2-3, pages 172-178.
Crossref
Crossref
Simon D. Brandt, Sally Freeman, Ian A. Fleet, Peter McGagh & John F. Alder. (2005) Analytical chemistry of synthetic routes to psychoactive tryptamines : Part II. Characterisation of the Speeter and Anthony synthetic route to N,N-dialkylated tryptamines using GC-EI-ITMS, ESI-TQ-MS-MS and NMR. The Analyst 130:3, pages 330.
Crossref
Crossref
Simon D. Brandt, Sally Freeman, Peter McGagh, Norliza Abdul-Halim & John F. Alder. (2004) An analytical perspective on favoured synthetic routes to the psychoactive tryptamines. Journal of Pharmaceutical and Biomedical Analysis 36:4, pages 675-691.
Crossref
Crossref
David E Nichols. (2004) Hallucinogens. Pharmacology & Therapeutics 101:2, pages 131-181.
Crossref
Crossref